IWR-1 NEW
| Price | $50 | $76 | $168 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-29 |
Product Details
| Product Name: IWR-1 | CAS No.: 1127442-82-3 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2026/05/29 |
Product Introduction
Bioactivity
| Name | IWR-1 |
| Description | IWR-1 (IWR-1-endo) is a tankyrase inhibitor that targets the Wnt/β-catenin pathway, with an IC?? of 180 nM. IWR-1 contributes to the activation of TCF/LEF and the expression of downstream targets of the Wnt/β-catenin pathway. IWR-1 promotes β-catenin phosphorylation by enhancing the stability of the Axin-mediated disassembly complex. IWR-1 can be used in research on diseases such as cancer and psoriasis. |
| In vitro | Methods: Human colorectal cancer cell lines HCT116 and HT29 were treated with IWR-1 at concentrations of 5, 10, 20, and 50 μM for 24 and 48 hours. Cell proliferation was assessed using the MTT/CCK-8 assay. Results: IWR-1 exhibited concentration- and time-dependent inhibition of cell proliferation. [1] |
| In vivo | Methods: Psoriasiform skin inflammation was induced in Balb/c mice by applying imiquimod cream to the dorsal skin daily for 5 consecutive days. On days 1, 3, and 5, mice received subcutaneous injections of IWR-1 (10 mg/kg) or IL-36γ (2 μg/mouse). After the fifth day of treatment, mice were euthanized, and dorsal skin tissue was harvested for subsequent analysis. Results: IL-36γ treatment significantly exacerbated IMQ-induced PASI scores, while IWR-1 treatment significantly suppressed IL-36γ-induced increases in PASI scores. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 85.8 mg/mL (209.55 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4.1 mg/mL (10.01 mM), Suspension. |
| Keywords | βcatenin | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt | IWR-1 | IWR1 | IWR 1 | Inhibitor | inhibit | beta-catenin | betacatenin | bcatenin |
| Inhibitors Related | Chlorquinaldol | Urea | Wnt pathway activator 1 | Neohesperidin | XAV-939 | Ethyl linoleate | Monensin sodium salt | Nimbolide | Isoquercetin | (±)-Nornicotine | Methyl Vanillate | Bisdemethoxycurcumin |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Anti-Prostate Cancer Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-26 | ||
| $999.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-06-26 | |
|
VIP8Y
|
ROSEWA HOLDING GROUP CO.,LIMITED
|
2026-06-25 | ||
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2019-12-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY